ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years
Changjing Huang
Matched on OpenAlex author ID A5014254241. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 16
2023: 1 paper · 2024: 2 papers
Papers 3
- Digital subtraction angiography-guided pancreatic arterial infusion of GEMOX chemotherapy in advanced pancreatic adenocarcinoma: a phase II, open-label, random… Co-author DOI 10.1186/s12885-024-12695-8↗
- SUMO3 inhibition by butyric acid suppresses cell viability and glycolysis and promotes gemcitabine antitumor activity in pancreatic cancer. Co-author DOI 10.1186/s13062-024-00513-x↗
- Circulating tumor-associated autoantibodies as novel diagnostic biomarkers in pancreatic adenocarcinoma. First author DOI 10.1002/ijc.34334↗
Closest collaborators
The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Yehua Shen · 2 shared papers, 2024 · strength 0.46
- Paper SUMO3 inhibition by butyric acid suppresses cell viability and glycolysis and promotes gemcitabine antitumor activity i… DOI 10.1186/s13062-024-00513-x↗
- Paper Digital subtraction angiography-guided pancreatic arterial infusion of GEMOX chemotherapy in advanced pancreatic adenoc… DOI 10.1186/s12885-024-12695-8↗
- Chien‐shan Cheng · 2 shared papers, 2023–2024 · strength 0.40
- Huifeng Gao · 1 shared paper, 2024 · strength 0.26
- Gang Chen · 1 shared paper, 2024 · strength 0.26
- Liming Zhu · 1 shared paper, 2024 · strength 0.26
- Yongqiang Hua · 1 shared paper, 2024 · strength 0.20
- Hao Chen · 1 shared paper, 2024 · strength 0.20
- Lanyun Feng · 1 shared paper, 2024 · strength 0.20
- Zhen Chen · 1 shared paper, 2024 · strength 0.20
- Peng Wang · 1 shared paper, 2024 · strength 0.20
- Zhiqiang Meng · 1 shared paper, 2024 · strength 0.20
- Zhouyu Ning · 1 shared paper, 2023 · strength 0.19
- Wen‐Bin Zou · 1 shared paper, 2023 · strength 0.19
- Peng Wang · 1 shared paper, 2023 · strength 0.19
- Liping Zhuang · 1 shared paper, 2023 · strength 0.19
- Zhiqiang Meng · 1 shared paper, 2023 · strength 0.19
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.